Life Tech, VelaDx Ink Sequencing-based Dx Deal

Oct 09, 2012

|

NEW YORK (GenomeWeb News) – Life Technologies today said that it has signed a licensing and supply deal with VelaDx providing the Singapore-based firm rights to develop clinical diagnostic tests on Life Tech's Ion Personal Genome Machine platform.

Under the terms of the deal VelaDx will seek regulatory approvals from global authorities to sell clinical tests for oncology and infectious disease applications. Further terms of the alliance were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Second One From Kite

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Worth the Price?

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Beyond Counting Tree Rings

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

This Week in Nature

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.

Main menu